Domestic medical reform enters the attack area while，Pharmaceutical companies accelerate the use of internationalization to find new markets。

 

  & ldquo; From last year to this year，Chinese pharmaceutical companies face the dual pressure of rising costs and decline in drug prices，But after adjusting the development of the Chinese pharmaceutical industry to a new stage。& rdquo; July 5，At the 9th China Biological Industry Conference，Wang Xuehai, Chairman of Renfu Pharmaceutical Group Co., Ltd.，Enterprises should improve the level of research and development，At the same time, we must actively move towards the international market。

 

  This understanding of Wang Xuehai has been confirmed by the market。Current，Domestic pharmaceutical companies have accelerated the development space in overseas markets，A set of statistical data show，From 2016 to the present，Three cases of overseas mergers and acquisitions in Chinese pharmaceutical companies have occurred，The scale of the three mergers and acquisitions is close to 1.5 billion US dollars。

 

   & ldquo; Compared with previous years，This year's merger and acquisition scale expanded，Add mergers and acquisition cases。& rdquo; An industry researcher who requires anonymous anonymous said to the 21st Century Business Herald reporter，Compared with the domestic market，More space in overseas markets，Pharmaceutical companies accelerate the search for new space in the international market。In addition to mergers and acquisitions，And domestic enterprises add yards stake betting appin the export market，To expand the company's international market share。But the vicious competition of funds and the vicious competition in the industry may test domestic pharmaceutical companies to go global。

 

  Overseas mergers and acquisitions have arrived

 

  Incant Status Classics，From 2011 to the present，There have been about 13 cases of overseas mergers and acquisitions in domestic pharmaceutical companies。

 

   & ldquo; Among these acquisition projects，It is mainly concentrated in Europe, America and Australia，But the willingness to be sold in pharmaceutical companies in other countries and regions in recent countries is enhanced。& rdquo; Researchers pointed out the above，Where，Pharmaceuticals, Japan, also has a number of pharmaceutical companies that will sell patents to expire pharmaceutical companies，Ruyanye Pharmaceutical has decided to sell infectious diseases to a foreign pharmaceutical company，Ansailai Pharmaceutical also plans to sell their digestive system diseases and other drugs。

 

  Liu Wei, a researcher at the Big Health Industry of China Investment Consultant, said，Frequent medical mergers and acquisitions systems of various countries，Drug research and development、Internationalization process acceleration in production standards and pharmaceutical technology，Created a good condition for the international mergers and acquisitions of the pharmaceutical industry，Make overseas pharmaceutical companies increase the possibility of being acquired by high valuations。

 

  In the international market，Some pharmaceutical companies are coming with the patent expire，The size of its own enterprise is not large enough。For example, Japan，The top -ranking pharmaceutical company's own sales scale is not high in the global scale，It will face the pressure of new drug research and development investment。& ldquo; So，They sell these pharmaceutical companies one after another。& rdquo; The above researcher also said，and the top pharmaceutical companies in the international market are already very large，In the process of previous globalization progress，Multi -country strategy has been completed，In the face of these assets to be sold, it is not much interest，This has reduced the difficulty of overseas mergers and acquisitions of pharmaceutical companies in other scale。

 

  Exports are mostly raw medicines

 

  Chinese companies have to seize this kind of opportunity to conduct overseas mergers and acquisitions stake online sports betting& ldquo; kinetic energy & rdquo;。

 

  A set of reference data display provided by Wang Xuehai in the speech，2014，In the export of drug exports of major countries and economies in the world，China's total exports are 13.4 billion US dollars，while the United States is $ 48.7 billion、India is $ 13.1 billion。& ldquo; In recent years，The total export of Chinese drugs has been maintained around 12th。& rdquo; Wang Xuehai expressed this。

 

  2015，The import amount of Chinese pharmaceutical products is 56.44 billion US dollars，Exit is 46.197 billion US dollars，Where，The total export value of Chinese medicine is 3.779 billion US dollars，Western medicine is about $ 31.5 billion，Medical equipment category is US $ 21.17 billion，But most of the medical equipment products are products with more low -quality consumption，For example, auxiliary materials and gauze。In the exit of western medicine，The proportion of raw materials is 81.3%，and the proportion of preparations is 18.7%。2014，This set of data is 82.4%and 17.6%, respectively，This data in 2013 was 82.2%and 17.8%。

 

   & ldquo; The total export of the preparation is increasing，The proportion of drug exports is rising slowly。& rdquo; Wang Xuehai said，Starting in 2011，The National Development and Reform Commission has produced the specialization of drug preparations for two consecutive years，This special special promotes the exit of the preparation。But in the country exported to China，Preparation is still mainly limited to some countries with weak economic strength。

 

  in the domestic market，China ’s pharmaceutical industry has overcapacity and is more serious，Need production capacity transfer。Liu Wei also said，Domestic enterprises accelerate the market overseas. The market is mainly because of the survival space of domestic pharmaceutical companies.，Especially small enterprises have been repeatedly compressed。In this context，Domestic enterprises accelerate the search for new development space in overseas markets，and mergers and acquisitions have become one of the means expanding overseas with higher efficiency。

 

  bumpy expansion

 

  But in the face of the expansion of overseas markets，Not so easy。Overseas market development path of Renfu Pharmaceutical has become a microcosm of domestic pharmaceutical companies looking for overseas markets。

 

  2009，Renfu Pharmaceutical officially decided to enter the international market，It establishes stake online sports bettingthe U.S. Poke Company，& ldquo; At first our approach was to do research and development and sales in the United States，Production in China & rdquo;，Wang Xuehai Memories，From the initial successful loss，To the preliminary foothold now，Live 7 years before and after。

 

  Starting from 2015，The United States finally turned to a profit，More than 20 medicines approved in the United States，More than 40 drugs have reached more than 40，Renfu Pharmaceutical also has a preliminary foothold in the US market。

 

  So，This year，Renfu Medicine accelerates expansion in the United States，Get acquired two US companies in the United States。& ldquo; After the acquisition of two American pharmaceutical factories，The number of drugs in the company in the United States has reached more than 110。& rdquo; Wang Xuehai revealed，From the perspective of the number of medicines，The company's ranking in the United States has entered the top 20，Among them, 7 products have the largest sales in the United States，Including cold medicines and some soft capsules products。

 

  To match the expansion of overseas markets，Human Fu Pharmaceuticals also built two production bases in Wuhan and Yichang, Hubei in China，Last year Wuhan's production base has obtained FDA certification，and Yichang base also passed the certification in May this year。

 

   & ldquo; Next step，Our idea is to further expand the number of products in our market in the US market。& rdquo; Wang Xuehai said，The company's idea is to learn from India，Current，On the US market，The top 10 companies in the market include three Indian companies，They did it for 2030 in the United States，That is, the relatively low -end OTC drugs at the beginning，Stand with the foothold through OTC drugs and enter the patented medicine and new drugs，Finally achieved amazing results，We also take this road，The level of industrial management of Chinese enterprises is not worse than Indian enterprises，It's just late to go out，Different is，We accelerate the chase，& ldquo; After five to ten years，Chinese drug preparations will have a place in the United States & rdquo;。

 

  Except the United States，Renfu Pharmaceutical is still expanding in other countries overseas。Introduction of Wang Xuehai，At present, the company has invested in the construction of a modern factory in West Africa，Pharmaceutical Stake Sports Bettingfactories in Ethiopia in East Africa have also laid the foundation，The company will also look for the right project in South Africa for the next step。

 

  but，The process of internationalization of Chinese pharmaceutical companies is still not easy。Wang Xuehai frankly，The company's registered research and development in the United States has invested nearly 800 million yuan。

 

  Another problem with Chinese pharmaceutical companies overseas expansion is the vicious competition and low -cost competition in China。Another pharmaceutical company also revealed，At present, the company is approved by a drug in overseas markets，But the other price reported by the peers is also obviously low。& ldquo; Competition in overseas markets，May fight a price war，I hope that domestic industry associations or relevant departments guide enterprises to avoid internal consumption。& rdquo;